Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001785530-26-000019
Filing Date
2026-07-31
Accepted
2026-07-31 07:10:41
Documents
70
Period of Report
2026-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q howl-20260630.htm   iXBRL 10-Q 1464440
2 EX-10.1 a06302026ex101.htm EX-10.1 360222
3 EX-10.2 a06302026ex102.htm EX-10.2 24689
4 EX-31.1 a06302026ex311.htm EX-31.1 10210
5 EX-31.2 a06302026ex312.htm EX-31.2 10247
6 EX-32.1 a06302026ex321.htm EX-32.1 6980
  Complete submission text file 0001785530-26-000019.txt   6615553

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT howl-20260630.xsd EX-101.SCH 41534
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT howl-20260630_cal.xml EX-101.CAL 49811
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT howl-20260630_def.xml EX-101.DEF 165822
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT howl-20260630_lab.xml EX-101.LAB 531601
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT howl-20260630_pre.xml EX-101.PRE 368899
74 EXTRACTED XBRL INSTANCE DOCUMENT howl-20260630_htm.xml XML 643923
Mailing Address 200 TALCOTT AVENUE 2ND FLOOR WATERTOWN MA 02472
Business Address 200 TALCOTT AVENUE 2ND FLOOR WATERTOWN MA 02472 617-952-0555
Werewolf Therapeutics, Inc. (Filer) CIK: 0001785530 (see all company filings)

EIN.: 823523180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40366 | Film No.: 261225406
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)